Literature DB >> 17130841

Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex.

J W Keller1, K M Haigis, J L Franklin, R H Whitehead, T Jacks, R J Coffey.   

Abstract

Activating mutations in members of the RAS family of genes are among the most common genetic events in human tumorigenesis. Once thought to be functionally interchangeable, it is increasingly recognized that the classical members of this protein family (H-RAS, N-RAS and K-RAS4B) exhibit unique and shared functions that are highly context-dependent. Herein, we demonstrate that the presence of an oncogenic KRAS allele results in elevated levels of GTP-bound N-RAS (N-RAS.GTP) in two human colorectal cancer cell lines, HCT 116 and DLD-1, compared to their isogenic counterparts in which the mutant KRAS allele has been disrupted by homologous recombination. N-RAS subserves an antiapoptotic role in cells expressing wild-type K-RAS; this function is compromised, however, by the presence of mutant K-RAS, and these cells display increased sensitivity to apoptotic stimuli. We additionally identify a physical interaction between N-RAS and gelsolin, a factor that has been shown to promote survival and show that the N-RAS:gelsolin complex is modulated differently in wild-type and mutant K-RAS environments following apoptotic challenge. These findings represent the first biochemical evidence of a functional relationship between endogenous RAS proteins and identify a dynamic physical interaction between endogenous N-RAS and gelsolin that correlates with survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17130841     DOI: 10.1038/sj.onc.1210103

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Integration of multiple signaling pathway activities resolves K-RAS/N-RAS mutation paradox in colon epithelial cell response to inflammatory cytokine stimulation.

Authors:  Pamela K Kreeger; Yufang Wang; Kevin M Haigis; Douglas A Lauffenburger
Journal:  Integr Biol (Camb)       Date:  2010-03-08       Impact factor: 2.192

2.  A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.

Authors:  Thomas McFall; Jolene K Diedrich; Meron Mengistu; Stacy L Littlechild; Kendra V Paskvan; Laura Sisk-Hackworth; James J Moresco; Andrey S Shaw; Edward C Stites
Journal:  Sci Signal       Date:  2019-09-24       Impact factor: 8.192

Review 3.  Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras.

Authors:  Sergia Velho; Kevin M Haigis
Journal:  Exp Cell Res       Date:  2011-06-17       Impact factor: 3.905

4.  Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.

Authors:  Michael A Morgan; Fredrick O Onono; H Peter Spielmann; Thangaiah Subramanian; Michaela Scherr; Letizia Venturini; Iris Dallmann; Arnold Ganser; Christoph W M Reuter
Journal:  J Mol Med (Berl)       Date:  2011-09-14       Impact factor: 4.599

5.  Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.

Authors:  Yufang Wang; Sérgia Velho; Efsevia Vakiani; Shouyong Peng; Adam J Bass; Gerald C Chu; Jessica Gierut; James M Bugni; Channing J Der; Mark Philips; David B Solit; Kevin M Haigis
Journal:  Cancer Discov       Date:  2012-12-28       Impact factor: 39.397

6.  Malignant transformation of colonic epithelial cells by a colon-derived long noncoding RNA.

Authors:  Jeffrey L Franklin; Carl R Rankin; Shawn Levy; Jay R Snoddy; Bing Zhang; Mary Kay Washington; J Michael Thomson; Robert H Whitehead; Robert J Coffey
Journal:  Biochem Biophys Res Commun       Date:  2013-09-14       Impact factor: 3.575

7.  RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects.

Authors:  Pamela K Kreeger; Roli Mandhana; Shannon K Alford; Kevin M Haigis; Douglas A Lauffenburger
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

8.  Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras.

Authors:  Ruby Shalom-Feuerstein; Ran Levy; Victoria Makovski; Avraham Raz; Yoel Kloog
Journal:  Biochim Biophys Acta       Date:  2008-03-25

Review 9.  Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer.

Authors:  Ken S Lau; Kevin M Haigis
Journal:  Mol Cells       Date:  2009-09-30       Impact factor: 5.034

10.  Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.

Authors:  H Charles Manning; Nipun B Merchant; A Coe Foutch; John M Virostko; Shelby K Wyatt; Chirayu Shah; Eliot T McKinley; Jingping Xie; Nathan J Mutic; M Kay Washington; Bonnie LaFleur; Mohammed Noor Tantawy; Todd E Peterson; M Sib Ansari; Ronald M Baldwin; Mace L Rothenberg; Darryl J Bornhop; John C Gore; Robert J Coffey
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.